Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 26, 2012

Antibody Labeling Turns Stressful

  • StressMarq Biosciences negotiated a nonexclusive commercial license to use U.K. firm Innova Biosciences’ Lightning-Link® technology for the development of antibody conjugate research tools. StressMarq offers a range of purified proteins as western blot controls and activity assays, along with a range of antibodies targeting cellular stress and ion channels and transporters, ELISA kits for cellular stress research (primary heat shock protein and DNA damage), and complementary small molecules, including inhibitors and activators of cellular pathways.

    Innova Biosciences specializes in bioconjugation (antibody labeling) technologies. Its flagship Lightning-Link platform has been designed to simplify the production of conjugates for research and immunodiagnostic applications, requiring just 30 seconds hands-on time, no separation steps, and 100% antibody recovery, the firm claims. More recently the firm launched the first in a prospective family of InnovaCoat™ Gold kit for the covalent conjugation of gold nanoparticles to antibodies, proteins, and biomolecules, which it claims allows the generation of ready-to-use antibody-gold conjugates in just 15 minutes.

    Innova in addition offers services for optimizing the performance of conjugates and the development of immunodiagnostic kits with improved sensitivity.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »